Star Trek has again shown the way after being the influence behind a new range of biotechnological devices from Nasa.
The dermal regenerator in Star Trek was a common, easily operable medical tool used by several civilizations to heal minor skin wounds, such as cuts and burns. The dermal regenerator could also be used to revert surgically modified skin to its normal state, as well as to remove scars. It could also be used to simulate wounds or burns.
Commander Riker and various other crew personnel from Star Trek The Next Generation would get cuts and bruises on away missions. Dr. Crusher would use a dermal regenerator to repair the damage instantly. From being science fiction could soon become a reality on board the International Space Station.
Nasa has signed a deal to create ‘novel biotechnology’ devices including a system that builds 3D human cells, and another that treats pain externally.
In the press release, NASA said it was “interested in the potential these technologies present for regenerating bone and muscle.” It wants this tissue regeneration technology to help astronauts during long interplanetary travel, when they “are susceptible to developing osteopenia, which is a condition arising from the loss of bone and muscle mass and bone density.”
GRoK will be able to use these patented methods on two platform technologies the company is developing.
The first platform, called BioReplicates, will allow users to create 3-D human tissue models that can be used to test cosmetics, drugs and other products for safety, efficacy and toxicity with greater accuracy, reliability and cost-efficiency. Additionally, using such models may reduce the industry’s reliance on animal testing.
The second platform, called Scionic, could lead to the development of medical devices designed to target musculoskeletal pain and inflammation in humans and animals noninvasively and without the use of pharmaceuticals.
“It’s not just science fiction anymore. All indications are that 21st century life sciences will change dramatically during the next several decades, and GRoK is working to define the forefront of a new scientific wave,” explained GRoK’s founder and CEO Moshe Kushman.